Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients.

British journal of haematology - 1 Feb 2013

Kok Chung H, Brown Anna L, Perugini Michelle, Iarossi Diana G, Lewis Ian D, D'Andrea Richard J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factors
Share to fms-Like Tyrosine Kinase 3
Share to FLT3 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to Survival Analysis

Source

Identifiers

PMID: 23190472
DOI: 10.1111/bjh.12131

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The preferential occurrence of FLT3-TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core-binding factor AML patients.PMID 23190472Read ↗

Prevalence and Clinical Outcome of FMS-Like Tyrosine Kinase Mutations Among Patients With Core Binding Factor-Acute Myeloid Leukemia: Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic abnormalities predict outcomes in patients with core binding factor acute myeloid leukemiaSemantic proximity Read ↗

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with RUNX1-RUNX1T1 or CBFB-MYH11 FusionsSemantic proximity Read ↗

Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.Semantic proximity Read ↗

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.Semantic proximity Read ↗

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patientsSemantic proximity Read ↗

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia.Semantic proximity Read ↗

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read ↗

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.